Skip to content

002720.KS

Kukje Pharma Co., Ltd.

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR

KRW 3,385.00
−0.88%
Ask drillr

Year over year

Reported trailing growth

Revenue
+8.0%
EBITDA
-73.3%
EBIT
-46.9%
EPS
-23.6%
Free cash flow
-64.2%
Operating cash flow
-22.8%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
+11.5%
EBITDA
-2.8%
EBIT
+5.5%
Net income
+17.0%
EPS
+16.8%
Free cash flow
-24.9%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026